RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+4.23%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.08B
AUM Growth
-$217M
(-4.1%)
Cap. Flow
+$263M
Cap. Flow
% of AUM
5.19%
Top 10 Holdings %
Top 10 Hldgs %
55.13%
Holding
68
New
14
Increased
10
Reduced
3
Closed
2
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$174M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$103M |
| 3 |
Evolent Health
EVH
|
$74.5M |
| 4 |
Taysha Gene Therapies
TSHA
|
$58.4M |
| 5 |
Apogee Therapeutics
APGE
|
$42.1M |
Top Sells
| 1 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$365M |
| 2 |
Ascendis Pharma
ASND
|
$47.4M |
| 3 |
Cytek Biosciences
CTKB
|
$30.3M |
| 4 |
Design Therapeutics
DSGN
|
$18.7M |
| 5 |
CureVac
CVAC
|
$11.2M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
GH Research
GHRS
$870M
| $56.2M | 1.11% |
5,587,333
| – | – |
|
|
ALPN
27
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $53.7M | 1.06% |
4,691,178
| – | – |
|
28
4D Molecular Therapeutics
FDMT
$287M
| $53M | 1.04% |
4,163,211
+1,093,680
| +36% | +$13.9M |
|
29
Fulcrum Therapeutics
FULC
$353M
| $51.5M | 1.01% |
11,609,704
| – | – |
|
|
ITOS
30
DELISTED
iTeos Therapeutics
ITOS
| $48.4M | 0.95% |
4,417,259
| – | – |
|
31
Vor Biopharma
VOR
$253M
| $48.2M | 0.95% |
22,748,880
| – | – |
|
|
ICVX
32
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $46.2M | 0.91% |
5,963,565
| – | – |
|
33
Acrivon Therapeutics
ACRV
$42.2M
| $46M | 0.91% |
4,810,508
| – | – |
|
|
34
Apogee Therapeutics
APGE
$2.27B
| $42.1M | 0.83% |
+1,977,901
| New | +$42.1M |
|
35
PepGen
PEPG
$39M
| $41.3M | 0.81% |
8,131,952
| – | – |
|
36
Avidity Biosciences
RNA
$6.12B
| $40.9M | 0.81% |
6,416,998
| – | – |
|
|
37
Cytek Biosciences
CTKB
$501M
| $37.6M | 0.74% |
6,809,404
-5,488,317
| -45% | -$30.3M |
|
38
Soleno Therapeutics
SLNO
$3.56B
| $36.6M | 0.72% |
+1,239,000
| New | +$36.6M |
|
39
ARS Pharmaceuticals
SPRY
$1.08B
| $35.8M | 0.7% |
9,459,678
+6,450,000
| +214% | +$24.4M |
|
|
CLYM
40
Climb Bio, Inc. Common Stock
CLYM
$151M
| $34.6M | 0.68% |
13,150,849
| – | – |
|
41
Viridian Therapeutics
VRDN
$1.59B
| $30.8M | 0.61% |
2,007,946
| – | – |
|
42
Pliant Therapeutics
PLRX
$105M
| $30.6M | 0.6% |
1,762,000
| – | – |
|
43
Mineralys Therapeutics
MLYS
$1.94B
| $30.2M | 0.6% |
3,178,476
| – | – |
|
44
Aclaris Therapeutics
ACRS
$223M
| $30.1M | 0.59% |
4,398,453
| – | – |
|
45
Madrigal Pharmaceuticals
MDGL
$9.7B
| $29.9M | 0.59% |
+204,500
| New | +$29.9M |
|
46
Enliven Therapeutics
ELVN
$1.24B
| $29M | 0.57% |
2,122,465
| – | – |
|
47
EyePoint Pharmaceuticals
EYPT
$827M
| $26.9M | 0.53% |
3,370,506
| – | – |
|
48
UroGen Pharma
URGN
$896M
| $20.8M | 0.41% |
+1,483,697
| New | +$20.8M |
|
49
Tenaya Therapeutics
TNYA
$192M
| $17.1M | 0.34% |
6,718,483
+651,000
| +11% | +$1.66M |
|
|
BCYC
50
Bicycle Therapeutics
BCYC
$492M
| $16.1M | 0.32% |
+800,000
| New | +$16.1M |
|